Transforming growth factor (TGF-) and insulin growth factor (IGF) are crucial in these processes, with GHK-Cu shown to decrease IGF-2-dependent TGF-1 secretion in dermal fibroblasts, potentially preventing hypertrophic scar formation
10.1038/nrm.2017.129 Nat
Patients focused on training recovery, joint support, or injury-related goals are more often evaluated for injectable protocols
Injectable Protocol (Systemic + Gut) For users who want systemic delivery alongside gut-targeted action: Loading Phase (Weeks 1 to 4): BPC-157: 250 to 500 mcg per day, subcutaneous injection (abdomen) KPV: 200 to 500 mcg per day, subcutaneous injection (abdomen) Maintenance Phase (Weeks 5 to 8): BPC-157: 250 mcg per day KPV: 200 to 300 mcg per day Extended Stack Options For enhanced regenerative effect beyond gut health, some practitioners add: TB-500: 2 to 2.5 mg twice weekly adds systemic cell migration and tissue remodeling for broader recovery GHK-Cu: 1 to 2 mg per day subcutaneous adds collagen production support and wound healing acceleration Timing and Administration Notes For oral gut-focused use, some users dose BPC-157 in the morning and KPV in the evening to maintain continuous coverage throughout the day
10.1523/JNEUROSCI.5524-09.2011 [DOI] [PMC free article] [PubMed] [Google Scholar] Warita H., Kato M., Asada R., Yamashita A., Hayata D., Adachi K., et al
Not a cure
